The University of Texas Health Science Center, Houston
This trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the context of smoking cessation.
Inclusion Criteria: * Ability to provide informed consent before any study-related activity, willing to comply with al study procedures, and be available for the duration of the study. * Body mass index (BMI) ≥30 kg/m2 or ≥27 kg/m2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension (unless meets medical exclusion criterion 7), cardiovascular disease (unless meets medical exclusion criterion 6), dyslipidemia, or obstructive sleep apnea * Have been smoking ≥5 cigarettes per day for at least 1 year (prior to screening) and provide…
Semaglutide 2.4mg will be self-administered once a week under the surface of the skin and will be started at 0.24mg or 0.25mg once a week for 4 weeks; in 4-week intervals, the dose will be increased until a dose of 2.4mg is reached
Non-active medication, self-administered
Participants who smoke \>10 cigarettes/day will use 21 mg patches for the first 6 weeks, 14 mg patches during weeks 7 and 8, and 7 mg patches during weeks 9 and 10. Participants who smoke 5-10 cigarettes per day will use 14 mg patches for the first 6 weeks and 7 mg patches for weeks 7-10.
Participants will receive weekly, manual-based individual smoking cessation counseling. Counseling will be provided by master's level clinicians.
Arctuva estimate
Verify or correct the compensation shown for this listing.